Paul Tudor Jones Reata Pharmaceuticals Inc Transaction History

Tudor Investment Corp Et Al

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$30.85 - $93.17 $671,296 - $2.03 Million	21,760 New	21,760 $1.98 Million
Q3 2022 Nov 14, 2022	BUY	$19.41 - $36.49 $5,861 - $11,019	302 Added 2.62%	11,833 $297,000
Q2 2022 Aug 15, 2022	SELL	$20.71 - $36.5 $34,047 - $60,006	-1,644 Reduced 12.48%	11,531 $350,000
Q1 2022 May 16, 2022	BUY	$24.12 - $39.6 $103,547 - $170,002	4,293 Added 48.33%	13,175 $432,000
Q4 2021 Feb 14, 2022	SELL	$25.61 - $110.96 $284,322 - $1.23 Million	-11,102 Reduced 55.55%	8,882 $234,000
Q3 2021 Nov 15, 2021	BUY	$100.0 - $143.02 $436,000 - $623,567	4,360 Added 27.91%	19,984 $2.01 Million
Q2 2021 Aug 16, 2021	SELL	$78.27 - $151.29 $505,702 - $977,484	-6,461 Reduced 29.26%	15,624 $2.21 Million
Q1 2021 May 17, 2021	BUY	$94.25 - $132.81 $834,960 - $1.18 Million	8,859 Added 66.98%	22,085 $2.2 Million
Q4 2020 Feb 16, 2021	BUY	$102.03 - $184.62 $1.35 Million - $2.44 Million	13,226 New	13,226 $1.64 Million
Q3 2020 Nov 16, 2020	SELL	$93.53 - $163.34 $717,000 - $1.25 Million	-7,666 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$126.3 - $176.56 $219,762 - $307,214	1,740 Added 29.36%	7,666 $1.2 Million
Q1 2020 May 15, 2020	SELL	$124.16 - $247.74 $290,534 - $579,711	-2,340 Reduced 28.31%	5,926 $855,000
Q4 2019 Feb 14, 2020	BUY	$74.57 - $217.92 $616,395 - $1.8 Million	8,266 New	8,266 $1.69 Million

62.7K

Ticker RETA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,583,200
Description
Reata Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, identifies, develops, and commercializes novel therapeutics for patients with serious or life-threatening diseases. The company is developing Phase 3 clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney diseas...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.